Niflumic acid


Concise Prescribing Info
Indications/Uses
Pain and inflammation associated w/ musculoskeletal and joint disorders.
Dosage/Direction for Use
Adult : PO 250 mg 3-4 times/day. Max: 1.5 g/day. Topical As 3% cream/oint or 2.5% gel: Apply as directed.
Dosage Details
Oral
Pain and inflammation associated with musculoskeletal and joint disorders
Adult: 250 mg 3 or 4 times daily. Max: 1500 mg daily.

Topical/Cutaneous
Pain and inflammation associated with musculoskeletal and joint disorders
Adult: 3% cream or ointment or 2.5% gel to be applied to affected areas.
Administration
Should be taken with food. Take w/ or immediately after meals.
Contraindications
Active peptic ulceration, severe heart failure.
Special Precautions
Discontinue if hypersensitivity skin reactions occur. Pregnancy, lactation. Elderly, patients with haemorrhagic disorders; hypertension; impaired renal, hepatic, cardiac function; asthma; infections; left ventricular failure; oedema; history of CHF.
Adverse Reactions
CNS disturbances, hypersensitivity reactions, renal/hepatic disorders, GI disturbances, cutaneous reactions, agranulocytosis, neutropenia. Fluid retention, photosensitivity, alveolitis, pulmonary eosinophilia, pancreatitis, Stevens-Johnson syndrome, exacerbation of colitis.
Drug Interactions
May increase concentration of methotrexate, cardiac glycosides. Increased risk of nephrotoxicity with ACE inhibitors, ciclosporin, tacrolimus, diuretics. Increased risk of GI bleeding with corticosteroids, SSRIs, venlafaxine, clopidogrel, ticlopidine, iloprost, erlotinib, sibutramine, alcohol, bisphosphonates, pentoxifylline.
Potentially Fatal: May reduce lithium excretion leading to lithium toxicity. May increase effects of anticoagulants.
Action
Description: Niflumic acid is an NSAID derived from nicotinic acid.
Disclaimer: This information is independently developed by MIMS based on Niflumic acid from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in